New drug targets Hard-to-Treat lung cancer mutation in major trial

NCT ID NCT07566052

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer. About 356 adults whose cancer worsened after prior treatments will be randomly assigned to one of the two drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Astera Cancer Care
RECRUITING

Edison, New Jersey, 08816, United States
Miyagi Cancer Center
RECRUITING

Natori-shi, Miyagi, Japan
Niigata Cancer Center Hospital
RECRUITING

Niigata, Japan
Oncura Health d.b.a.Los Angeles Cancer Network
RECRUITING

Glendale, California, 91204, United States
Virginia Cancer Specialists
RECRUITING

Arlington, Virginia, 22201, United States